{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:13:43Z","timestamp":1790738023954,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010763","name":"Zorginstituut Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jval.2019.07.007","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T17:23:09Z","timestamp":1567790589000},"page":"1275-1282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions"],"prefix":"10.1016","volume":"22","author":[{"given":"Rick A.","family":"Vreman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkatuuli","family":"Heikkinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad","family":"Schuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Sapede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi Llinares","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Hedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Athanasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Grueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert G.M.","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim G.","family":"Goettsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2019.07.007_bib3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/clpt.2011.345","article-title":"Adaptive licensing: taking the next step in the evolution of drug approval","volume":"91","author":"Eichler","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jval.2019.07.007_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cpt.59","article-title":"From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients","volume":"97","author":"Eichler","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jval.2019.07.007_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3389\/fphar.2017.00497","article-title":"Adaptive pathways: possible next steps for payers in preparation for their potential implementation","volume":"8","author":"Vella Bonanno","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jval.2019.07.007_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fphar.2016.00305","article-title":"Payers\u2019 views of the changes arising through the possible adoption of adaptive pathways","volume":"7","author":"Ermisch","year":"2016","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.jval.2019.07.007_bib7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/cpt.1251","article-title":"Weighing of evidence by health technology assessment bodies: retrospective study of reimbursement recommendations for conditionally approved drugs","volume":"105","author":"Vreman","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jval.2019.07.007_bib8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10198-016-0823-0","article-title":"Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries","volume":"18","author":"Nicod","year":"2017","journal-title":"Eur J Health Econ"},{"issue":"7","key":"10.1016\/j.jval.2019.07.007_bib9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.drudis.2011.10.027","article-title":"Determinants for successful marketing authorisation of orphan medicinal products in the EU","volume":"17","author":"Putzeist","year":"2012","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.jval.2019.07.007_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s13063-017-2287-7","article-title":"A\u00a0systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?","volume":"18","author":"Rath","year":"2017","journal-title":"Trials"},{"issue":"19","key":"10.1016\/j.jval.2019.07.007_bib11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.drudis.2013.06.012","article-title":"EU marketing authorization review of orphan and non-orphan drugs does not differ","volume":"18","author":"Putzeist","year":"2013","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.jval.2019.07.007_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.seminoncol.2017.02.009","article-title":"What constitutes an \u201cunmet medical need\u201d in oncology? An empirical evaluation of author usage in the biomedical literature","volume":"44","author":"Lu","year":"2017","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.jval.2019.07.007_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jval.2017.11.003","article-title":"Building synergy between regulatory and HTA agencies beyond processes and procedures\u2014can we effectively align the evidentiary requirements? A survey of stakeholder perceptions","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health"},{"issue":"7524","key":"10.1016\/j.jval.2019.07.007_bib14","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/bmj.38636.593461.68","article-title":"Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources","volume":"331","author":"Greenhalgh","year":"2005","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.jval.2019.07.007_bib15","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jval.2017.03.008","article-title":"What is real-world data? A review of definitions based on literature and stakeholder interviews","volume":"20","author":"Makady","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2019.07.007_bib16","unstructured":"Ministerie van Volksgezondheid W en S. Ziektelast in de praktijk - De theorie en praktijk van het berekenen van ziektelast bij pakketbeoordelingen - Rapport - Zorginstituut Nederland. https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2018\/05\/07\/ziektelast-in-de-praktijk. Accessed September 14,\u00a02018."},{"issue":"11","key":"10.1016\/j.jval.2019.07.007_bib17","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40273-015-0307-6","article-title":"Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness","volume":"33","author":"Svensson","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2019.07.007_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S0266462307051513","article-title":"Mapping the integration of social and ethical issues in health technology assessment","volume":"23","author":"Lehoux","year":"2007","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.jval.2019.07.007_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healthpol.2007.09.007","article-title":"Decision-making in priority setting for medicines\u2014a review of empirical studies","volume":"86","author":"Vuorenkoski","year":"2008","journal-title":"Health Policy"},{"issue":"2","key":"10.1016\/j.jval.2019.07.007_bib20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/0272989X11416870","article-title":"Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal","volume":"32","author":"Goetghebeur","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2019.07.007_bib21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12913-015-0930-0","article-title":"Balancing costs and benefits at different stages of medical innovation: a systematic review of multi-criteria decision analysis (MCDA)","volume":"15","author":"Wahlster","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10.1016\/j.jval.2019.07.007_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1099-1050(199703)6:2<117::AID-HEC256>3.0.CO;2-B","article-title":"Intergenerational equity: an exploration of the \u201cfair innings\u201d argument","volume":"6","author":"Williams","year":"1997","journal-title":"Health Econ"},{"issue":"12","key":"10.1016\/j.jval.2019.07.007_bib23","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1016\/S0277-9536(02)00244-7","article-title":"The rule of rescue","volume":"56","author":"McKie","year":"2003","journal-title":"Soc Sci Med"},{"issue":"6","key":"10.1016\/j.jval.2019.07.007_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.healthpol.2018.04.001","article-title":"Looking back and moving forward: on the application of proportional shortfall in healthcare priority setting in the Netherlands","volume":"122","author":"Reckers-Droog","year":"2018","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.jval.2019.07.007_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10728-018-0361-2","article-title":"Why we don\u2019t need \u201cunmet needs\u201d! On the concepts of unmet need and severity in health-care priority setting","volume":"27","author":"Sandman","year":"2019","journal-title":"Health Care Anal"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519323034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519323034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:16:13Z","timestamp":1761095773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301519323034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1098301519323034"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2019.07.007","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2019.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}